Free Trial

Aridis Pharmaceuticals (ARDS) Competitors

Aridis Pharmaceuticals logo
$0.0001 +0.00 (+∞)
As of 07/23/2025 03:27 PM Eastern

ARDS vs. SYRS, SCPS, VAXX, NAVB, EVLO, CMRA, GNCAQ, GNCA, STAB, and AMPE

Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Syros Pharmaceuticals (SYRS), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry.

Aridis Pharmaceuticals vs. Its Competitors

Syros Pharmaceuticals (NASDAQ:SYRS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Syros Pharmaceuticals presently has a consensus price target of $3.33, indicating a potential upside of 56,397.18%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Syros Pharmaceuticals is more favorable than Aridis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syros Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Aridis Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 11.59, meaning that its stock price is 1,059% more volatile than the S&P 500.

Aridis Pharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.41-$164.57M-$3.030.00
Aridis PharmaceuticalsN/AN/A-$30.37MN/AN/A

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Aridis Pharmaceuticals N/A N/A N/A

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Syros Pharmaceuticals beats Aridis Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

ARDS vs. The Competition

MetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5K$772.21M$5.71B$9.51B
Dividend YieldN/A4.84%4.60%3.99%
P/E RatioN/A1.3928.0720.02
Price / SalesN/A26.96459.47103.02
Price / CashN/A19.5636.5558.97
Price / BookN/A6.798.615.88
Net Income-$30.37M-$4.32M$3.24B$258.50M

Aridis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDS
Aridis Pharmaceuticals
N/A$0.00
+∞
N/AN/A$5KN/A0.0030Gap Up
SYRS
Syros Pharmaceuticals
4.134 of 5 stars
$0.00
-82.9%
$3.33
+555,455.6%
-99.7%$16K$386K0.00120Upcoming Earnings
Gap Up
SCPS
Scopus BioPharma
N/A$0.00
flat
N/AN/A$13KN/A0.009
VAXX
Vaxxinity
N/A$0.00
flat
N/A-56.0%$13KN/A0.0090Gap Up
NAVB
Navidea Biopharmaceuticals
N/A$0.00
flat
N/A-50.0%$10K$8.13K0.0010
EVLO
Evelo Biosciences
N/A$0.00
flat
N/AN/A$9KN/A0.00120News Coverage
Options Volume
CMRA
Comera Life Sciences
N/A$0.00
flat
N/AN/A$6K$1.00M0.002
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$6KN/A0.0070
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91M0.0070
STAB
Statera Biopharma
N/A$0.00
flat
N/A-83.3%$5KN/A0.0020Negative News
High Trading Volume
AMPE
Ampio Pharmaceuticals
N/A$0.00
-73.0%
N/A+145.5%$3KN/A0.0020Gap Down

Related Companies and Tools


This page (NASDAQ:ARDS) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners